CLBR 001 SWI 019 - Abbvie/California Institute for Biomedical Research
Alternative Names: CLBR-001+SWI-019; Switchable-CAR-T-cell-therapy - Abbvie/California Institute for Biomedical ResearchLatest Information Update: 14 Apr 2025
At a glance
- Originator AbbVie; California Institute for Biomedical Research
- Class Antineoplastics; CAR-T cell therapies; Fab fragments; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I B-cell lymphoma
Most Recent Events
- 14 Apr 2025 Calibr plans a phase I trial for Autoimmune disorders in May 2025 (NCT06913608)
- 06 May 2024 Calibr completes a phase-I trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (Parenteral, Infusion) (NCT04450069)
- 13 Apr 2023 Phase I clinical development in B-cell lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA (IV) (Abbvie pipeline, April 2023)